Negotiation or Coercion? Big Pharma and US Chamber of Commerce Tackle Government on Drug Prices
Portfolio Pulse from Vandana Singh
The U.S. Chamber of Commerce has filed a lawsuit against the federal government over a law allowing Medicare to negotiate drug prices with pharmaceutical companies. Merck, Pfizer, Bristol Myers Squibb, and AbbVie are among the companies affected by this law.
June 12, 2023 | 4:06 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AbbVie's Imbruvica is expected to be among the top-selling drugs subject to U.S. price negotiations for 2026, potentially impacting the company's revenues.
AbbVie's Imbruvica is expected to be among the top-selling drugs subject to U.S. price negotiations for 2026. If the program is implemented, it could lead to lower revenues for the company due to reduced drug prices.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75
NEGATIVE IMPACT
Bristol Myers Squibb's Eliquis is expected to be among the top-selling drugs subject to U.S. price negotiations for 2026, potentially impacting the company's revenues.
Bristol Myers Squibb's Eliquis is expected to be among the top-selling drugs subject to U.S. price negotiations for 2026. If the program is implemented, it could lead to lower revenues for the company due to reduced drug prices.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75
NEGATIVE IMPACT
Merck filed a lawsuit against the U.S. government to halt the Medicare drug price negotiation program, which could impact the company's revenues.
Merck is directly involved in the lawsuit against the U.S. government, challenging the Medicare drug price negotiation program. If the program is implemented, it could lead to lower revenues for the company due to reduced drug prices.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75
NEGATIVE IMPACT
Pfizer's CEO criticized U.S. plans to negotiate drug prices for Medicare, which could negatively impact the company's revenues.
Pfizer's CEO has expressed strong opposition to the U.S. government's plans to negotiate drug prices for Medicare. If the program is implemented, it could lead to lower revenues for the company due to reduced drug prices.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75